TheBlackList Pub

For All Points-Of-The-View.

OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study - with findings related to younger women, African Americans and Hispanics

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced preliminary clinical observations related to its pilot biomarker OMS-I140 clinical trial of ImmunoPulse® IL-12 in patients with metastatic Triple Negative Breast Cancer (TNBC). The study is designed to assess whether a single cycle of ImmunoPulse IL-12 increases TNBC tumor immunogenicity by driving a pro-inflammatory cascade of events including activation of cytotoxic tumor-infiltrating lymphocytes (TILs).   

To date, five patients with TNBC have been treated with a single cycle of ImmunoPulse IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with electroporation). Two of these five patients were subsequently treated with single agent nivolumab (Opdivo®) - an anti-PD-1 checkpoint inhibitor treatment - as their immediate next therapy. Both of these patients, who were heavily pretreated metastatic TNBC patients with chemotherapy refractory disease, experienced robust objective responses in both ImmunoPulse IL-12 treated and untreated lesions. These clinical observations have prompted the Company to further commit to a more definitive evaluation of the combined therapies.

"Metastatic TNBC is a heterogeneous cancer with a poor prognosis where less than five percent of pre-treated patients achieve an objective response to PD-1/PD-L1 checkpoint treatments," explained Sharron Gargosky, Chief Clinical and Regulatory Officer of OncoSec. "The marked synergy shown in these patients strongly suggests that IL-12 may have primed the tumor microenvironment, impacting the clinical result. The combination of ImmunoPulse IL-12 and checkpoint inhibition represents a highly promising new therapeutic approach for TNBC and warrants a formal evaluation given the extremely low response rate in women who have failed multiple prior therapies."

Previous studies have demonstrated that breast cancer patients whose tumors are associated with markers of inflammation, such as the presence of TILs, achieve better clinical outcomes. In addition, the density of TILs is a key requirement for the anti-tumor activity of immune checkpoint inhibitors like anti-PD-1/PD-L1 antibodies. By augmenting the expansion of CD8+ tumor infilatrating T cells, ImmunoPulse IL-12 may be an ideal candidate to combine with checkpoint inhibitors, which has demonstrated low and variable activity as a monotherapy in TNBC.

Immunological examination of samples from all patients are currently being analyzed. These data, along with the full information regarding clinical observations and safety data, will be submitted for presentation at an upcoming medical meeting in 2018.

To learn more about the trial, visit www.oncosec.com. Additional details can also be found atwww.clinicaltrials.gov via NCT02531425.

OPDIVO® is a registered trademark of Bristol-Myers Squibb Company.

ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA.

About Triple Negative Breast Cancer (TNBC)
Breast cancer cells that test negative for estrogen receptors (ER-), progesterone receptors (PR-), and HER2 (HER2-) means the cancer is triple negative.1 Approximately 15-20 percent of US breast cancer cases are triple negative breast cancer (TNBC),2 which disproportionately affects younger women as well as African-American women, followed by Hispanic women.3
CONTINUE FOR MORE

Views: 7


Donations Accepted

 

Discussion Forum

OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study - with findings related to younger women, African Americans and Hispanics

Started by SendMeYourNews Jan 20. 0 Replies

OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study - with findings related to younger women, African Americans and Hispanics https://t.co/xE67HJv8SE…Continue

Number One New Year’s Resolution for Men: Get screened for Prostate Cancer

Started by TheBlackList-Publisher Dec 31, 2017. 0 Replies

Santa Rosa urologist and prostate cancer expert Dr. Michael Lazar provides an overview of prostate cancer screening options; says early detection saves lives.“Knowing the many options for treating prostate cancer is something all men at risk of…Continue

Lupus in Pregnancy: Tips for Mothers-To-Be

Started by Bronx Scoop Dec 21, 2017. 0 Replies

Lupus does not reduce the odds of becoming pregnant—however,…Continue

5 Women Who Died From Butt Injections

Started by SendMeYourNews. Last reply by Zhana Dec 22, 2017. 1 Reply

Many women have died from illegal cosmetic procedures performed by…Continue

Why Black women are 3 to 4 times more likely to die during childbirth

Started by TheBlackList-Publisher. Last reply by Lyonezz Dec 12, 2017. 1 Reply

Praeclarus Press announces a new book by…Continue

The Reilly Center at the University of Notre Dame Releases Its 2018 Top 10 List of Ethical Dilemmas in Science and Technology

Started by TheBlackList-Publisher Dec 7, 2017. 0 Replies

The John J. Reilly Center for Science, Technology, and Values at the University of Notre Dame has released its sixth annual list of emerging ethical dilemmas and policy issues in science and technology. The annual list is designed to get people…Continue

Events

February 2018
SMTWTFS
123
45678910
11121314151617
18192021222324
25262728
       

© 2018   Created by KWASI Akyeampong.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Offline

Live Video

= = http://theblacklist.net/